Abstract
AbstractThe adenoviral vector based AstraZeneca and Janssen COVID vaccines have been associated with rare cases of thrombosis, a condition which depends on adenovirus binding to the blood protein Platelet Factor 4 (PF4).In order to identify adenoviruses with low or absent affinity for PF4, we screened dozens of types from various adenovirus species, and Adenovirus type 5 (Ad5) derived vectors carrying genetic or chemical modifications of different hexon hyper-variable regions (HVR). For this purpose, we established an armamentarium of techniques including ELISA-qPCR and Aggregate Pull-Down (APD), which enabled fast and sensitive assessments of virus-protein interactions.Unlike most tested serotypes, Ad34 did not bind to PF4. Likewise, the deletion or shielding of the HVR1 loop of Ad5 seemingly ablated its PF4 binding. Therefore, we showed that PF4 binds to adenovirus hexon through interactions dependent on HVR1, and identified vectors that may avoid or decrease the risk of thrombosis and represent safer candidates for vaccine or gene therapy vector development.
Publisher
Cold Spring Harbor Laboratory
Reference36 articles.
1. Genetic content and evolution of adenoviruses
2. human Adenovirus working group, (available at http://hadvwg.gmu.edu/).
3. Adenovirus vector-based vaccine for infectious diseases
4. Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine;Genes Dis,2017
5. M. Head , What happened to the AstraZeneca vaccine? Now rare in rich countries, it’s still saving lives around the world. The Conversation (2022), (available at https://theconversation.com/what-happened-to-the-astrazeneca-vaccine-now-rare-in-rich-countries-its-still-saving-lives-around-the-world-181791).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献